Montelukast Krka

Montelukast, the active ingredient in Montelukast Krka, is a leukotriene receptor antagonist presented as a tablet for oral use. It is used to manage asthma, allergic rhinitis, and to prevent exercise‑induced bronchospasm in adults and children. It works by blocking cysteinyl leukotriene receptors that contribute to airway inflammation and bronchoconstriction.

GNH USA supplies Montelukast Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for cross‑border procurement.

Montelukast is indicated for conditions involving leukotriene‑mediated inflammation, primarily within the respiratory tract.

- Asthma: improves long‑term control and reduces exacerbations in adults and children. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergies. - Exercise‑induced bronchospasm: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: non‑productive respiratory irritation. - Nasopharyngitis: inflammation of the nasal passages and throat. - Dyspepsia: indigestion with bloating or nausea. - Diarrhea: loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation. - Nausea: feeling of sickness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis requiring immediate medical attention. - Neuropsychiatric events: agitation, depression, suicidal thoughts or behavior. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Eosinophilic granulomatosis with polyangiitis: rare vasculitic disorder. - Stevens‑Johnson syndrome: severe skin reaction.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

- Assess asthma control: confirm that the patient requires add‑on therapy before initiation. - Monitor neuropsychiatric symptoms: watch for mood changes, depression or suicidal thoughts. - Avoid in hypersensitivity: discontinue if signs of allergic reaction appear. - Use with caution in hepatic impairment: dose adjustment may be needed in severe liver disease. - Review concomitant drugs: consider potential interactions that may alter montelukast levels. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Montelukast can interact with other medicines, affecting its plasma concentration or therapeutic effect.

Major Interactions (Avoid): - Ritonavir: strong CYP3A4 inhibition markedly increases montelukast exposure. - Phenobarbital, carbamazepine, phenytoin: potent CYP inducers markedly decrease montelukast levels. - Gemfibrozil: may increase montelukast concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP3A4 inhibition may raise montelukast levels. - Ketoconazole: similar effect requiring observation. - Warfarin: potential alteration of anticoagulant effect; monitor INR. - St. John’s wort: herbal inducer that can reduce efficacy.